Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HICALIQ RF
- Development stage
- Unknown
- Lead developer
- Terumo
- Modality
- Small Molecules
- Administration
- Intravenously
01
Overview
HICALIQ RF is a prescription medication in Japan used as a base solution for total parenteral nutrition, specifically formulated for patients who require electrolytes adjusted for renal function, such as those with chronic kidney disease or those undergoing dialysis[3][7]. It is a non-amine electrolyte and dextrose solution, designed to provide essential nutrients and electrolytes in a formulation that is safe for patients with impaired renal function. The product is developed and manufactured by Terumo Corporation.
- Brand names
- HICALIQ RF
Beyond the preview
Go deeper on HICALIQ RF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HICALIQ RF.